Aiding sleep in type 2 diabetes: therapeutic considerations

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 1, 2018, Pages 60-68

  Tan, Xiao ^a   van Egmond, Lieve ^a   Chapman, Colin D ^a   Cedernaes, Jonathan ^a   Benedict, Christian ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; MELATONIN; MELATONIN RECEPTOR AGONIST; SUVOREXANT;

AEROBIC EXERCISE; ANXIETY DISORDER; BLOOD GLUCOSE MONITORING; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DIABETIC PATIENT; DIET; DIET THERAPY; DISEASE COURSE; DIZZINESS; EVIDENCE BASED MEDICINE; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REM SLEEP; REVIEW; SLEEP; SLEEP DISORDERED BREATHING; SLEEP TIME; TREATMENT RESPONSE; WITHDRAWAL SYNDROME; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

DIABETES MELLITUS, TYPE 2; HUMANS; PROGNOSIS; SLEEP APNEA, OBSTRUCTIVE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 85028329084     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30233-4     Document Type: Review

References (99)

1. Gupta, S, Wang, Z, Predictors of sleep disorders among patients with type 2 diabetes mellitus. Diabetes Metab Syndr 10 (2016), 213–220.
2. American Academy of Sleep Medicine. International classification of sleep disorders, 3rd edn, 2014, American Academy of Sleep Medicine, Darien, IL.
3. Tasali, E, Leproult, R, Ehrmann, DA, Van Cauter, E, Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA 105 (2008), 1044–1049.
4. Herzog, N, Jauch-Chara, K, Hyzy, F, et al. Selective slow wave sleep but not rapid eye movement sleep suppression impairs morning glucose tolerance in healthy men. Psychoneuroendocrinology 38 (2013), 2075–2082.
5. Schmid, SM, Hallschmid, M, Jauch-Chara, K, et al. Disturbed glucoregulatory response to food intake after moderate sleep restriction. Sleep 34 (2011), 371–377.
6. Cedernaes, J, Lampola, L, Axelsson, EK, et al. A single night of partial sleep loss impairs fasting insulin sensitivity but does not affect cephalic phase insulin release in young men. J Sleep Res 25 (2016), 5–10.
7. Rao, MN, Neylan, TC, Grunfeld, C, Mulligan, K, Schambelan, M, Schwarz, JM, Subchronic sleep restriction causes tissue-specific insulin resistance. J Clin Endocrinol Metab 100 (2015), 1664–1671.
8. Heffner, JE, Rozenfeld, Y, Kai, M, Stephens, EA, Brown, LK, Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. Chest 141 (2012), 1414–1421.
9. Einhorn, D, Stewart, DA, Erman, MK, Gordon, N, Philis-Tsimikas, A, Casal, E, Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr Pract 13 (2007), 355–362.
10. Foster, GD, Sanders, MH, Millman, R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 32 (2009), 1017–1019.
11. Aronsohn, RS, Whitmore, H, Van Cauter, E, Tasali, E, Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 181 (2010), 507–513.
12. Berry, RB, Brooks, R, Gamaldo, CE, et al., for the American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Version 2.3, 2016, American Academy of Sleep Medicine, Darien, IL.
13. Johns, MW, A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14 (1991), 540–545.
14. Peppard, PE, Young, T, Barnet, JH, Palta, M, Hagen, EW, Hla, KM, Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177 (2013), 1006–1014.
15. Martínez-Ceron, E, Fernández-Navarro, I, Garcia-Rio, F, Effects of continuous positive airway pressure treatment on glucose metabolism in patients with obstructive sleep apnea. Sleep Med Rev 25 (2016), 121–130.
16. Lee, SW, Ng, KY, Chin, WK, The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. Sleep Med Rev 31 (2017), 91–101.
17. Cizza, G, Piaggi, P, Rother, KI, Csako, G, Sleep Extension Study Group. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS One, 9, 2014, e104176.
18. Leproult, R, Deliens, G, Gilson, M, Peigneux, P, Beneficial impact of sleep extension on fasting insulin sensitivity in adults with habitual sleep restriction. Sleep 38 (2015), 707–715.
19. Carroll, JE, Seeman, TE, Olmstead, R, et al. Improved sleep quality in older adults with insomnia reduces biomarkers of disease risk: pilot results from a randomized controlled comparative efficacy trial. Psychoneuroendocrinology 55 (2015), 184–192.
20. Huedo-Medina, TB, Kirsch, I, Middlemass, J, Klonizakis, M, Siriwardena, AN, Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ, 345, 2012, e8343.
21. Holbrook, AM, Crowther, R, Lotter, A, Cheng, C, King, D, Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 162 (2000), 225–233.
22. Terzano, MG, Rossi, M, Palomba, V, Smerieri, A, Parrino, L, New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 26 (2003), 261–282.
23. Tyrer, P, Why benzodiazepines are not going away. Advan Psychiatr Treat 18 (2012), 259–262.
24. Grigsby, AB, Anderson, RJ, Freedland, KE, Clouse, RE, Lustman, PJ, Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 53 (2002), 1053–1060.
25. Plantinga, L, Rao, MN, Schillinger, D, Prevalence of self-reported sleep problems among people with diabetes in the United States, 2005–2008. Prev Chronic Dis, 9, 2012, E76.
26. Budhiraja, R, Roth, T, Hudgel, DW, Budhiraja, P, Drake, CL, Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep 34 (2011), 859–867.
27. Mast, R, Rauh, SP, Groeneveld, L, et al. The use of antidepressants, anxiolytics, and hypnotics in people with type 2 diabetes and patterns associated with use: the hoorn diabetes care system cohort. BioMed Research International, 2017, 10.1155/2017/5134602 published online Jan 23.
28. Huerta, C, Abbing-Karahagopian, V, Requena, G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf 25 (2016), 56–65.
29. Gramaglia, E, Ramella Gigliardi, V, Olivetti, I, et al. Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects. J Endocrinol Invest 37 (2014), 203–206.
30. Lin, CL, Yeh, MC, Harnod, T, Lin, CL, Kao, CH, Risk of type 2 diabetes in patients with nonapnea sleep disorders in using different types of hypnotics: a population-based retrospective cohort study. Medicine (Baltimore), 94, 2015, e1621.
31. Ma, J, Svetnik, V, Snyder, E, Lines, C, Roth, T, Herring, WJ, Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 37 (2014), 1609–1619.
32. Armitage, R, Lee, J, Bertram, H, Hoffmann, R, A preliminary study of slow-wave EEG activity and insulin sensitivity in adolescents. Sleep Med 14 (2013), 257–260.
33. Arendt, J, Skene, DJ, Melatonin as a chronobiotic. Sleep Med Rev 9 (2005), 25–39.
34. Herxheimer, A, Petrie, KJ, Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev, 2, 2002, CD001520.
35. Clarke, TC, Black, LI, Stussman, BJ, et al. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Report 79 (2015), 1–16.
36. Ferracioli-Oda, E, Qawasmi, A, Bloch, MH, Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One, 8, 2013, e63773.
37. Arendt, J, Does melatonin improve sleep? Efficacy of melatonin. BMJ, 332, 2006, 550.
38. Sateia, MJ, Buysse, DJ, Krystal, AD, Neubauer, DN, Heald, JL, Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 13 (2017), 307–349.
39. Burke, TM, Markwald, RR, Chinoy, ED, et al. Combination of light and melatonin time cues for phase advancing the human circadian clock. Sleep 36 (2013), 1617–1624.
40. van Geijlswijk, IM, Korzilius, HP, Smits, MG, The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 33 (2010), 1605–1614.
41. Anothaisintawee, T, Lertrattananon, D, Thamakaison, S, Knutson, KL, Thakkinstian, A, Reutrakul, S, Later chronotype is associated with higher hemoglobin A1c in prediabetes patients. Chronobiol Int 34 (2017), 393–402.
42. McMullan, CJ, Schernhammer, ES, Rimm, EB, Hu, FB, Forman, JP, Melatonin secretion and the incidence of type 2 diabetes. JAMA 309 (2013), 1388–1396.
43. Rubio-Sastre, P, Scheer, FA, Gómez-Abellán, P, Madrid, JA, Garaulet, M, Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep 37 (2014), 1715–1719.
44. Tuomi, T, Nagorny, CL, Singh, P, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab 23 (2016), 1067–1077.
45. Laudon, M, Frydman-Marom, A, Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci 15 (2014), 15924–15950.
46. Kuriyama, A, Honda, M, Hayashino, Y, Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med 15 (2014), 385–392.
47. Tsunoda, T, Yamada, M, Akiyama, T, et al. The effects of ramelteon on glucose metabolism and sleep quality in type 2 diabetic patients with insomnia: a pilot prospective randomized controlled trial. J Clin Med Res 8 (2016), 878–887.
48. Herring, WJ, Snyder, E, Budd, K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79 (2012), 2265–2274.
49. Michelson, D, Snyder, E, Paradis, E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 13 (2014), 461–471.
50. Kripke, DF, Is suvorexant a better choice than alternative hypnotics?. F1000Res, 4, 2015, 456.
51. Tsuneki, H, Kon, K, Ito, H, et al. Timed inhibition of orexin system by suvorexant improved sleep and glucose metabolism in type 2 diabetic db/db mice. Endocrinology 157 (2016), 4146–4157.
52. Trauer, JM, Qian, MY, Doyle, JS, Rajaratnam, SM, Cunnington, D, Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 163 (2015), 191–204.
53. Morin, CM, Vallières, A, Guay, B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 301 (2009), 2005–2015.
54. Ho, FY, Chung, KF, Yeung, WF, et al. Self-help cognitive-behavioral therapy for insomnia: a meta-analysis of randomized controlled trials. Sleep Med Rev 19 (2015), 17–28.
55. Reynolds, AC, Dorrian, J, Liu, PY, et al. Impact of five nights of sleep restriction on glucose metabolism, leptin and testosterone in young adult men. PLoS One, 7, 2012, e41218.
56. Schmid, SM, Hallschmid, M, Schultes, B, The metabolic burden of sleep loss. Lancet Diabetes Endocrinol 3 (2015), 52–62.
57. Krystal, AD, Edinger, JD, Sleep EEG predictors and correlates of the response to cognitive behavioral therapy for insomnia. Sleep 33 (2010), 669–677.
58. Espie, CA, Kyle, SD, Williams, C, et al. A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep 35 (2012), 769–781.
59. Giles, TL, Lasserson, TJ, Smith, BJ, White, J, Wright, J, Cates, CJ, Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev, 3, 2006, CD001106.
60. Yang, D, Liu, Z, Yang, H, Luo, Q, Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 17 (2013), 33–38.
61. Gallegos, L, Dharia, T, Gadegbeku, AB, Effect of continuous positive airway pressure on type 2 diabetes mellitus and glucose metabolism. Hosp Pract (1995) 42 (2014), 31–37.
62. Martínez-Cerón, E, Barquiel, B, Bezos, AM, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes. A randomized clinical trial. Am J Respir Crit Care Med 194 (2016), 476–485.
63. Krentz, AJ, Bailey, CJ, Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65 (2005), 385–411.
64. Frenţ ŞM, Tudorache, VM, Ardelean, C, Mihăicuţă S, Long-term effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea. Pneumologia 63:204 (2014), 207–211.
65. Grimaldi, D, Beccuti, G, Touma, C, Van Cauter, E, Mokhlesi, B, Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. Diabetes Care 37 (2014), 355–363.
66. Pamidi, S, Wroblewski, K, Stepien, M, et al. Eight hours of nightly continuous positive airway pressure treatment of obstructive sleep apnea improves glucose metabolism in patients with prediabetes. A randomized controlled trial. Am J Respir Crit Care Med 192 (2015), 96–105.
67. Mokhlesi, B, Grimaldi, D, Beccuti, G, et al. Effect of one week of 8-hour nightly Continuous positive airway pressure treatment of obstructive sleep apnea on glycemic control in type 2 diabetes: a proof-of-concept study. Am J Respir Crit Care Med 194 (2016), 516–519.
68. West, SD, Nicoll, DJ, Wallace, TM, Matthews, DR, Stradling, JR, Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 62 (2007), 969–974.
69. Wolkove, N, Baltzan, M, Kamel, H, Dabrusin, R, Palayew, M, Long-term compliance with continuous positive airway pressure in patients with obstructive sleep apnea. Can Respir J 15 (2008), 365–369.
70. Young, LR, Taxin, ZH, Norman, RG, Walsleben, JA, Rapoport, DM, Ayappa, I, Response to CPAP withdrawal in patients with mild versus severe obstructive sleep apnea/hypopnea syndrome. Sleep 36 (2013), 405–412.
71. Richards, D, Bartlett, DJ, Wong, K, Malouff, J, Grunstein, RR, Increased adherence to CPAP with a group cognitive behavioral treatment intervention: a randomized trial. Sleep 30 (2007), 635–640.
72. Ramar, K, Dort, LC, Katz, SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med 11 (2015), 773–827.
73. Phillips, CL, Grunstein, RR, Darendeliler, MA, et al. Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med, 187, 2013, 187.
74. Caples, SM, Rowley, JA, Prinsell, JR, et al. Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis. Sleep 33 (2010), 1396–1407.
75. Strollo, PJ Jr, Soose, RJ, Maurer, JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med 370 (2014), 139–149.
76. Kay-Stacey, M, Attarian, H, Advances in the management of chronic insomnia. BMJ, 354, 2016, i2123.
77. King, AC, Pruitt, LA, Woo, S, et al. Effects of moderate-intensity exercise on polysomnographic and subjective sleep quality in older adults with mild to moderate sleep complaints. J Gerontol A Biol Sci Med Sci 63 (2008), 997–1004.
78. Passos, GS, Poyares, D, Santana, MG, et al. Effects of moderate aerobic exercise training on chronic primary insomnia. Sleep Med 12 (2011), 1018–1027.
79. Tan, X, Alén, M, Wiklund, P, Partinen, M, Cheng, S, Effects of aerobic exercise on home-based sleep among overweight and obese men with chronic insomnia symptoms: a randomized controlled trial. Sleep Med 25 (2016), 113–121.
80. Iftikhar, IH, Kline, CE, Youngstedt, SD, Effects of exercise training on sleep apnea: a meta-analysis. Lung 192 (2014), 175–184.
81. Umpierre, D, Ribeiro, PA, Kramer, CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 305 (2011), 1790–1799.
82. Yang, PY, Ho, KH, Chen, HC, Chien, MY, Exercise training improves sleep quality in middle-aged and older adults with sleep problems: a systematic review. J Physiother 58 (2012), 157–163.
83. Reusch, JE, Bridenstine, M, Regensteiner, JG, Reusch JE, Bridenstine M, Regensteiner JG. Type 2 diabetes mellitus and exercise impairment. Rev Endocr Metab Disord 14 (2013), 77–86.
84. De Feo, P, Schwarz, P, Is physical exercise a core therapeutical element for most patients with type 2 diabetes?. Diabetes Care 36 (2013), S149–S154.
85. Phillips, F, Crisp, AH, Mcguinness, B, et al. Isocaloric diet changes and electroencephalographic sleep. Lancet 306 (1975), 723–725.
86. St-Onge, MP, Mikic, A, Pietrolungo, CE, Effects of diet on sleep quality. Adv Nutr 7 (2016), 938–949.
87. St-Onge, MP, Roberts, A, Shechter, A, Choudhury, AR, Fiber and saturated fat are associated with sleep arousals and slow wave sleep. J Clin Sleep Med 12 (2016), 19–24.
88. Tan, X, Alén, M, Wang, K, et al. Effect of six-month diet intervention on sleep among overweight and obese men with chronic insomnia symptoms: a randomized controlled trial. Nutrients, 8, 2016, E751.
89. Araghi, MH, Chen, YF, Jagielski, A, et al. Effectiveness of lifestyle interventions on obstructive sleep apnea (OSA): systematic review and meta-analysis. Sleep 36 (2013), 1553–1562.
90. Foster, GD, Borradaile, KE, Sanders, MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 169 (2009), 1619–1626.
91. Franz, MJ, Bantle, JP, Beebe, CA, et al., for the American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 27:suppl 1 (2004), S36–S46.
92. American Diabetes Association. 6. Obesity management for the treatment of type 2 diabetes. Diabetes Care 39:supp l (2016), S47–S51.
93. Reutrakul, S, Hood, MM, Crowley, SJ, et al. Chronotype is independently associated with glycemic control in type 2 diabetes. Diabetes Care 36 (2013), 2523–2529.
94. Morselli, LL, Guyon, A, Spiegel, K, Sleep and metabolic function. Pflugers Arch 463 (2012), 139–160.
95. Anothaisintawee, T, Reutrakul, S, Van Cauter, E, Thakkinstian, A, Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. Sleep Med Rev 30 (2016), 11–24.
96. Cedernaes, J, Lampola, L, Axelsson, EK, et al. A single night of partial sleep loss impairs fasting insulin sensitivity but does not affect cephalic phase insulin release in young men. J Sleep Res 25 (2016), 5–10.
97. Cedernaes, J, Schiöth, HB, Benedict, C, Determinants of shortened, disrupted, and mistimed sleep and associated metabolic health consequences in healthy humans. Diabetes 64 (2015), 1073–1080.
98. Luyster, FS, Dunbar-Jacob, J, Sleep quality and quality of life in adults with type 2 diabetes. Diabetes Educ 37 (2011), 347–355.
99. Lecube, A, Sánchez, E, Gómez-Peralta, F, et al. Global assessment of the impact of type 2 diabetes on sleep through specific questionnaires. A case-control study. PLoS One, 11, 2016, e0157579.